A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours

Summary

This is an open-label, fixed-sequence study to evaluate the effect of capivasertib on the pharmacokinetics (PK) of midazolam, a sensitive CYP3A substrate. The PK of midazolam will be assessed when administered alone and in combination with repeated doses of capivasertib.

Timeline

Start

2021-10-15

Primary completion

2023-02-06

Completion

2023-02-15

Publications

• Miller C, Sommavilla R, O'Bryant CL, Barve M, Dowlati A, Luke JJ, Khatun M, Morris T, Cullberg M. Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2024 Aug;94(2):223-235. doi: 10.1007/s00280-024-04667-3. Epub 2024 Apr 20.

Drugs

Indications